ArticleOncotarget2017

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.

Eliza Vakana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.